Related Experiment Videos

The potential regulatory relationship between hsa_circ_0000973 and MBOAT2 in hypertriglyceridemia with abnormal

Fengdan Wang1, Yixue Yang2, Xiaotong Li1

  • 1Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, No. 1163 Xinmin Street, Chaoyang District, Changchun 130021, P. R. China.

Human Molecular Genetics
|August 6, 2026
PubMed

Insights

Abnormal glucose metabolism (AGM) patients with hypertriglyceridemia (HTG) show decreased hsa_circ_0000973 and MBOAT2. hsa_circ_0000973 is a potential biomarker for HTG in AGM, potentially regulating TG metabolism with MBOAT2.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Hypertriglyceridemia (HTG) is common in abnormal glucose metabolism (AGM) populations, increasing health risks.
  • Preliminary research identified hsa_circ_0000973 and MBOAT2 as potential regulators of HTG in AGM patients.

Purpose of the Study:

  • To investigate the role and mechanism of hsa_circ_0000973 and MBOAT2 in AGM-associated HTG.
  • To evaluate hsa_circ_0000973 as a diagnostic biomarker for HTG in AGM patients.

Main Methods:

  • RT-qPCR to measure expression levels of hsa_circ_0000973 and MBOAT2 in 142 AGM subjects.
  • ROC analysis for diagnostic performance evaluation.
  • siRNA-mediated knockdown of hsa_circ_0000973 or MBOAT2 in insulin-resistant HepG2 cells for functional validation.

Main Results:

  • Both hsa_circ_0000973 and MBOAT2 were significantly downregulated in AGM patients with HTG and negatively correlated with serum TG levels.
  • hsa_circ_0000973 demonstrated high diagnostic accuracy for HTG in AGM (AUC = 0.95).
  • Knockdown of either hsa_circ_0000973 or MBOAT2 in HepG2-IR cells led to increased TG accumulation, altered glucose metabolism, reduced proliferation, and increased apoptosis, affecting lipid metabolism transcription factors.

Conclusions:

  • hsa_circ_0000973 is a potential biomarker for identifying HTG in the AGM population.
  • hsa_circ_0000973 may jointly regulate triglyceride metabolism with MBOAT2 in the context of AGM.

Keywords:
MBOAT2glucose metabolismhsa_circ_0000973insulin resistancetriglyceride

Related Concept Videos

Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.